Investment

ARDD 2020: Addressing the challenges in drug discovery

We speak to the co-founder of Molecule about building a unique marketplace for early stage therapeutic development. Next week (September 1 - 4), the annual...

The billionaires are coming!

Longevity Investors Conference aims to focus the investment spotlight on developments in anti-aging science. As Greg Bailey told us last week: "When I was talking...

AgeTech investment: “there is everything to play for”

AgeTech Accelerator's Lorraine Morley on market disconnect, helping investors take the plunge and shaping the AgeTech market. Continuing our series of interviews with our Advisory Panel...

Longevity opportunities in the post-Covid world

Longevity International’s Tina Woods discusses how Covid-19 has catapulted health to the top of the global agenda. Tina Woods is CEO and co-founder of Longevity...

$85m funding for epigenetic platform technology

Omega Therapeutics secures $85m to carry out clinical trials into epigenetic treatments for five key disease areas – and potentially for Covid-19.  While you might...

Tonus seeks early-stage funding for exoskeleton tech

Company spawned by London start-up generator targets middle-aged recreational athletes with exoskeleton leggings powered by soft robotics. Back in November, we brought you the story...

SENISCA seeks funding for senescence reversal

University of Exeter spinout raising seed investment as it targets aging aesthetics and age-related disease with ground-breaking rejuvenation technology. Deep in the labs at the...

SyndicateRoom co-founder joins First Longevity

Tom Britton joins Advisory Panel as plans for Longevity equity funding platform take another step forward. Longevity.Technology: Just last month we announced the formation of...

Longevity investment: Apollo aims for the moon

Co-founder of Longevity-focused investment firm shows you can target aging AND appeal to biotech investors. Founded in 2016, Berlin and Boston-based Apollo already boasts an...

Cosmetic therapeutic senolytics: aging isn’t just skin-deep

When is a cosmetic product also a therapy? When it's a patented senolytic that tackles aging at a cellular level. OneSkin began life validating how...

Unlocking the Longevity potential of our oceans

Biologist focuses on the coast of Oman to discover how extreme environments and oceanic life could provide sources for Longevity. With issues like climate change, overfishing...

G3 and Juvenescence partner on deep learning venture

G3 Therapeutics and Juvenescence announce the formation of Juvenomics to apply deep molecular profiling and deep learning to tackle aging. Juvenomics, a joint venture between...

New initiative offers boost for health innovators

A new health tech accelerator aims to support small businesses and enterprises in the fight against the aging process. The UK's Industrial Strategy Challenge Fund has...

Fountain Therapeutics inks new $6m finance deal

New funding for AI and computer vision Longevity drug discovery start-up. The saying goes: “Some people drink from the fountain of knowledge. Others just gargle.”...

Jim Mellon donates £1 million to Oriel for aging research

Oxford University's Longevity science given a £1 million boost by donation. Oriel College, Oxford, is a focal point for the efforts to improve future health...

The next generation of Longevity investment

What’s driving Kingsley Advani to get involved in the fight against aging? What do Juvenescence, Oisín Biotechnologies, Volumetric and GEn1E Lifesciences have in common? Yes,...

Applying theoretical physics to Longevity drug discovery

Peter Fedichev's Gero raising $10 million for anti-aging drug discovery and clinical trials. The use of AI in Longevity drug discovery is nothing new, Insilico...

Regenerative medicine start-up raises $28.5 million

A Baltimore based biotech start-up, LifeSprout, has closed a $28.5million round of series A financing as it prepares for the launch of clinical trials...

Longevity2020: Day 4 recap

Yesterday at Longevity2020 was all about how the Longevity sector is growing an investment category. Speakers included top investors, as well as the entrepreneurs behind...

Oisín on aging as a disease and raising $5m seed

Co-founder Gary Hudson talks cell senescence, trials, spin-outs and the dilemma of treating age as a disease. Every entrepreneur in Longevity has a different story...

Latest articles

Peptide molecule causes cancer cells to self destruct

New breakthrough by a team led by eminent oncologist Loren Walensky brings new hope for future cancer treatments – and Longevity.  Everyone needs a way...

WHO portal brings aging data together

We live in a world driven by data and the World Health Organization (WHO) has now launched the first data portal to bring together...

The natural medicine war chest to fight aging

Quicksilver's liposomal delivery system boasts a non-invasion of the body patchers. Colorado-based Quicksilver Scientific manufactures a range of supplements from immunity boosters to NAD+. By...

Jim Mellon and Phil Newman: Longevity interviews

Master Investor is a publication that helps private investors to take charge of their financial destiny: covering a range of subjects, from shares to...